[go: up one dir, main page]

MX2007000892A - A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4- yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3- pyridinicarbox amide hemisuccinate salt. - Google Patents

A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4- yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3- pyridinicarbox amide hemisuccinate salt.

Info

Publication number
MX2007000892A
MX2007000892A MX2007000892A MX2007000892A MX2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A MX 2007000892 A MX2007000892 A MX 2007000892A
Authority
MX
Mexico
Prior art keywords
carbazol
yloxy
methylpropyl
phenoxy
hydroxypropyl
Prior art date
Application number
MX2007000892A
Other languages
Spanish (es)
Inventor
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2007000892A publication Critical patent/MX2007000892A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a crystalline variable hydrate of (S)-(3- pyridinecarboxamide, 6-[4-[2-[[3-(9H- carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate,a pharmaceutical formulation containing said salt and to methods for treatingobesity and/or Type 2 diabetes using said salt.
MX2007000892A 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4- yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3- pyridinicarbox amide hemisuccinate salt. MX2007000892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59025104P 2004-07-22 2004-07-22
PCT/US2005/024886 WO2006019835A1 (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt

Publications (1)

Publication Number Publication Date
MX2007000892A true MX2007000892A (en) 2007-05-23

Family

ID=35106749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000892A MX2007000892A (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4- yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3- pyridinicarbox amide hemisuccinate salt.

Country Status (17)

Country Link
US (1) US7834187B2 (en)
EP (2) EP1773811B1 (en)
JP (1) JP4922163B2 (en)
CN (1) CN1989129B (en)
AT (1) ATE480534T1 (en)
AU (1) AU2005275185B2 (en)
BR (1) BRPI0513569A2 (en)
CA (1) CA2572631C (en)
CY (1) CY1110806T1 (en)
DE (1) DE602005023474D1 (en)
DK (1) DK1773811T3 (en)
ES (1) ES2349798T3 (en)
MX (1) MX2007000892A (en)
PL (1) PL1773811T3 (en)
PT (1) PT1773811E (en)
SI (1) SI1773811T1 (en)
WO (1) WO2006019835A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
ES2171839T3 (en) * 1996-09-05 2002-09-16 Lilly Co Eli CARBAZOL ANALOGS AS BETA3 SELECTIVE ADRENERGIC AGONISTS.
EP1204655B1 (en) * 1999-07-29 2003-10-01 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
AR035355A1 (en) * 2000-10-20 2004-05-12 Lilly Co Eli A NEW CRYSTALLINE SHAPE OF 6-HYDROXI-3- (4- (2- (PIPERIDIN-1-IL) ETOXI) PHENOXI) -2- (4-METOXYPHENYL) BENZO (B) THIOPHEN
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
HRP20040112B1 (en) * 2001-08-15 2012-03-31 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Also Published As

Publication number Publication date
US7834187B2 (en) 2010-11-16
CY1110806T1 (en) 2015-06-10
BRPI0513569A2 (en) 2012-10-09
ES2349798T3 (en) 2011-01-11
CA2572631C (en) 2012-05-15
JP4922163B2 (en) 2012-04-25
EP1773811B1 (en) 2010-09-08
AU2005275185A1 (en) 2006-02-23
WO2006019835A1 (en) 2006-02-23
CN1989129A (en) 2007-06-27
AU2005275185B2 (en) 2011-06-23
CA2572631A1 (en) 2006-02-23
EP2233482A1 (en) 2010-09-29
CN1989129B (en) 2010-11-10
PT1773811E (en) 2010-10-19
ATE480534T1 (en) 2010-09-15
JP2008507519A (en) 2008-03-13
DK1773811T3 (en) 2010-12-13
SI1773811T1 (en) 2011-01-31
PL1773811T3 (en) 2011-02-28
US20080058385A1 (en) 2008-03-06
DE602005023474D1 (en) 2010-10-21
EP1773811A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
UA85686C2 (en) Ethyl 3-(n-(2-(4-(hexyloxycarbonylamidino)ph enylaminomethyl)-1-methyl-1h-benzimidazole-5-carbonyl)-n-(2-pyridyl)a mino)propionate methanesulfonate, use thereof as a medicament and process for the preparation thereof
DK1682536T3 (en) PROCEDURE FOR PREPARING THE CALCIUM SALT OF ROSUVASTATIN (E) -7- [4- (4-FLUORPHENYL) -6-ISOPROPYL-2- [METHYL (METHYLSULPHONYL) AMINO] -PYRIMIDIN-5-YL] (3) 5-DIHYDROXYHEPT-6-ACID AND CRYSTALLINIC INTERMEDIATES THEREOF
NO20071320L (en) Pyrazole-substituted amino heteroaryl compounds as protein kinase inhibitors.
MY149140A (en) Hydrates of 2-chloro 5-y3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoro-methyl)-1-(2h)-pyrimidinyl"-4-fluoro-n- yymethyl-(1-methylethyl)-amino"sulphonyl"benzamide
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
DE60316013D1 (en) HETEROARYL PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
HUP0200301A3 (en) Process for the production of tert-butyl (e)-(6-[2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4r,6s)-2,2-dimethyl[1,3]dioxan-4-yl)acetate
PT1263739E (en) Crystalline salts of 7-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6-enoic acid
PE20060243A1 (en) DERIVATIVES OF 4-AMINO INSUSTITUTED-5- (4-UREA-PHENYL) -PYRROLOTRIAZINE
PE20060873A1 (en) HETEROAROMATIC QUINOLINE COMPOUNDS
RU2009149216A (en) BICYCLIC AMIDES AS KINASE INHIBITORS
DK1533304T3 (en) amide derivative
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND PROCESS FOR PREPARING THE SAME
PE20121476A1 (en) COMPOSITION FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY THE KINASE ACTIVITY OF BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
ATE347550T1 (en) POLYMORPHOUS OF 4-(2-(4-(1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL)-1-PIPERIDINYL)ETHYL)-ALPHA, ALPHA-DIMETHYLBENZENEACETIC ACID
MX2007000892A (en) A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4- yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3- pyridinicarbox amide hemisuccinate salt.
ATE256678T1 (en) 4-(2-PYRIDYL)PIPERAZINE AS AN AGONIST OF THE 5HT7 RECEPTOR
DK1565440T3 (en) New Process for Preparation of 2-Aminomethylpyridine Derivatives
TW200700410A (en) Besylate salt of 7-(2-(4-(3-(trifluoromethyl)phenyl) -1,2,3,6-tetrahydropyrid-1-yl)ethyl) isoquinoline, its preparation and its use in therapeutics
AU2003235814A8 (en) Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2006079556A3 (en) Substituted 5-phenyl pyrimidines i in therapy

Legal Events

Date Code Title Description
FG Grant or registration